Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin

Journal of Pharmaceutical Sciences

Volumn 92, Issue 5, 2003, Pages 1085-1094

  Cavalli, Roberta ^a   Bargoni, Alessandro ^a   Podio, Valerio ^b   Muntoni, Elisabetta ^a   Zara, Gian Paolo ^a   Gasco, Maria Rosa ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Enteral absorption; Lymphatic uptake; Pharmacokinetics parameters; Solid lipid nanoparticles; Tobramycin

Indexed keywords

SOLID LIPID NANOPARTICLE; TOBRAMYCIN;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DIFFUSION; DRUG TRANSPORT; HYDROPHILICITY; IN VITRO STUDY; INTESTINE ABSORPTION; JUGULAR VEIN; LIPOPHILICITY; MALE; NONHUMAN; PARTICLE SIZE; RAT; SUSTAINED RELEASE PREPARATION; TRANSMISSION ELECTRON MICROSCOPY; TRANSPORT KINETICS;

EID: 0242684665     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10368     Document Type: Article

References (30)

1. Muranishi S. 1991. Drug targeting towards the lymphatics. Adv Drug Res 21:1-38.
2. Oussoren C, Storm G. 1997. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: Influence of liposomal size, lipid composition, and lipid dose. Biochim Biophys Acta 1328: 261-272.
3. Velinova M, Read N, Kirby C, Gregoriadis G. 1996. Morphological observations on the fate of liposomes in the regional lymph nodes after footpad injection into rats. Biochim Biophys Acta 1299:207-215.
4. 14C-polyacrylic nanoparticles. Arch Pharmacol 324:637-641.
5. Damge C, Mitchel C, Aprahamian M, Couvreur P, Devissaguet JP. 1990. Nanocapsules as carriers for oral peptide delivery. J Controlled Release 13:233-239.
6. Hawley AE, Illum L, Davis SS. 1997. Preparation of biodegradable, surface engineered PLGA nanospheres with enhanced lymphatic drainage and lymph node uptake. Pharm Res 14:657-661
7. Porter CJH, Charman WN. 2001. Intestinal lymphatic drug transport: An update. Adv Drug Deliv Rev 50:61-80.
8. Caliph SM, Charman WN, Porter CJH. 2000. Effect of short-, medium-and long-chain fatty acid based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non cannulated rats. J Pharm Sci 89:1073-1084.
9. Müller RH, Mader K, Gohla S. 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art. Eur J Pharm Biopharm 50:161-177.
10. Westesen K, Bunjes H, Koch HJ. 1997. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Controlled Release 48:223-236.
11. Yang S, Zhu J, Lu Y, Liang B, Yang C. 1999. Body distribution of camptothecin solid lipid Nanoparticles after oral administration. Pharm Res 16:751-757.
12. Lukowski G, Pflegel P. 1997. Evaluation diffraction of solid lipid nanoparticles loaded with aciclovir. Pharmazie 52:642-643.
13. Ahlin P, Kristl J, Šentjurc M, Štrancar J, Pecar S. 2000. Influence of spin probe structure on its distribution in SLN dispersions. Int J Pharm 196: 241-244.
14. Gasco MR. 1997. Solid lipid nanospheres from warm micro-emulsions. Pharm Technol Eur 9: 52-58.
15. Gasco MR. 2001. Solid lipid nanoparticles for drug delivery. Pharm Technol Eur 13:32-41.
16. Bargoni A, Cavalli R, Caputo O, Fundarò A, Gasco MR, Zara GP. 1998. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm Res 15:745-750.
17. Zara GP, Bargoni A, Cavalli R, Fundar A, Vighetto D, Gasco MR. 2002. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J Pharm Sci 91:1324-1333.
18. Cavalli R, Zara GP, Caputo O, Bargoni A, Fundarò A, Gasco MR. 2000. Transmucosal transport of tobramycin incorporated in SLN after duodenal administration to rats. Part I - A pharmacokinetic study. Pharmacol Res 42:541-545.
19. Cavalli R, Gasco MR, Morel S. 1992. Behavior of timolol in lipospheres in the presence of a series of phosphate esters. STP Pharm Sci 6:514-518.
20. Cavalli R, Caputo O, Gasco MR. 1993. Solid lipospheres of doxorubicin and idarubicin. Int J Pharm 89:R9-R10.
21. Brown DA, Malkin T, Maliphant GK. 1955. An X-ray examination of long-chain alkyldihydrogen phosphates and dialkylhydrohgen phosphates and their sodium salts. J Chem Soc 1584-1588.
22. Cavalli R, Gallarate M, Gasco MR. 1999. Incorporation of tobramycin into solid lipid nanospheres as ion-pair complexes. Acta Technol Legis Medicam X:17-27.
23. Sampath SS, Robinson DH. 1995. Comparison of new and existing spectrophotometric methods for the analysis of tobramycin and other aminoglycosides. J Pharm Sci 79:428-431.
24. Koppel DE. 1972. Analysis of macromolecular polydispersity in intensity correlation spectroscopy: The method of cumulant. J Chem Phys 57:4814-4818.
25. Walker SE, Coates PE. 1981. High performance liquid chromatographic method for determination of gentimicin in biological fluids. J Chromatogr 223:131-138.
26. Florence AT, Hillery M, Jani PU. 1995. Factors affecting the oral uptake and traslocation of polystirene nanoparticles: Hystological and analytical evidence. J Drug Targeting 3:65-70.
27. Nishioka Y, Yoshino H. 2001. Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev 47:55-64.
28. Florence AT. 1997. The oral absorption of micro-and nanoparticulate: Neither exceptional nor usual. Pharm Res 14:259-266.
29. Krishna R, Webb MS, Onge G, Mayer LD. 2001. Liposomal andd non liposomal drug pharamcokinetics after administraton of liposome-emcapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther 298:1206-1212.
30. Working PK, Dayan DD. 1996. Pharmacological-toxicological expert report. CAELIX (Stealth liposomal doxorubicin HCl). Human Exp Toxicol 15: 751-785.